153 related articles for article (PubMed ID: 11740050)
1. Neuroendocrine marker expression in thyroid epithelial tumors.
Satoh F; Umemura S; Yasuda M; Osamura RY
Endocr Pathol; 2001; 12(3):291-9. PubMed ID: 11740050
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in non-neuroendocrine thyroid carcinoma.
Kargi A; Yörükoglu ; Aktaş S; Cakalagaoglu ; Ermete M
Thyroid; 1996 Jun; 6(3):207-10. PubMed ID: 8837328
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study.
Slodkowska J; Zych J; Szturmowicz M; Demkow U; Rowinska-Zakrzewska E; Roszkowski-Sliz K
Int J Biol Markers; 2005; 20(4):217-26. PubMed ID: 16398403
[TBL] [Abstract][Full Text] [Related]
4. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
7. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
8. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
Hashimoto T; Matsubara F; Mizukami Y; Miyazaki I; Michigishi T; Yanaihara N
Endocrinol Jpn; 1990 Apr; 37(2):247-54. PubMed ID: 1699752
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
12. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of the neural cell adhesion molecule NCAM 140 in human pituitary tumors.
Aletsee-Ufrecht MC; Langley K; Gratzl O; Gratzl M
FEBS Lett; 1990 Oct; 272(1-2):45-9. PubMed ID: 2121537
[TBL] [Abstract][Full Text] [Related]
14. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine marker expression in cervical carcinomas of non-small cell type.
Chavez-Blanco A; Taja-Chayeb L; Cetina L; Chanona-Vilchis G; Trejo-Becerril C; Perez-Cardenas E; Segura-Pacheco B; Acuña-González C; Dueñas-Gonzalez A
Int J Gynecol Pathol; 2002 Oct; 21(4):368-74. PubMed ID: 12352185
[TBL] [Abstract][Full Text] [Related]
16. Clinical implication of neuroendocrine differentiation in prostatic adenocarcinomas.
Constantinides C; Pavlaki K; Zizi D; Gavriel J; Mitropoulos D; Garifalos J; Dimopoulos C
Urol Int; 1995; 55(3):134-6. PubMed ID: 8540155
[TBL] [Abstract][Full Text] [Related]
17. The expression of keratins, vimentin, neurofilament proteins, smooth muscle actin, neuron-specific enolase, and synaptophysin in tumors of the specific glands in the canine anal region.
Vos JH; van den Ingh TS; Ramaekers FC; Molenbeek RF; de Neijs M; van Mil FN; Ivanyi D
Vet Pathol; 1993 Jul; 30(4):352-61. PubMed ID: 8212457
[TBL] [Abstract][Full Text] [Related]
18. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
19. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
20. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
